Nouveau Biosciences Announces the Appointment of Dr. Diane Mould to its Scientific Advisory Board

[New York, NY – November 3, 2026] – Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has appointed the world-renowned pharmacologist Dr. Diane Mould

Dr. Mould has been at the forefront of pharmacokinetics and pharmacodynamics over the past 30 plus years, having been involved in countless FDA New Drug Applications (NDA) to the agency, including hematopoietic agents, monoclonal antibodies, anti-cancer and anti-viral drugs, cardiovascular and a variety of neuropsychiatric agents. She has specialized in population pharmacokinetic and pharmacodynamic modeling and developed mathematical models to individualize doses of drug that are challenging to manage. This experience has made her one of the worlds authorities in the field, and has acted as a valued advisor to virtually every major pharmaceutical industry in the field, and prestigious institutions like Memorial Sloan Kettering Cancer Center and the National Institutes of Health (NIH).

“I have had the pleasure of knowing and working with Diane now for nearly 25 years. There is simply no greater intellect in this field. Her mathematical modeling skills, coupled to a deep knowledge of the pharmacodynamic science makes her one of the most respected scientists I have encountered in this field in decades”, said Owen A. O’Connor, M.D., Ph.D., Founder and CEO of Nouveau Biosciences.

Dr. Mould is also the Founder and Chief Scientific Officer at Baysient, a company that develops computational approaches to individualized dosing of drugs which exhibit challenging pharmacologic features, and is the Founder and President of Projections Research, specializing in PK and PD modelling and exposure-response/exposure-adverse event assessments. “Most scientists and physicians engaged in drug discovery and development don’t often appreciate the importance of PK/PD modelling. It is refreshing to see Nouveau’s approach, which not only values the science, but sees it as mission critical as they develop state-of-the-art nanomedicines for cancer”, says Dr. Mould. “I could not be more excited to work with such an esteemed group of scientists and leaders from the industry”.

Dr. Mould is a Fellow of the American College of Clinical Pharmacology and a Fellow of the American Association of Pharmaceutical sciences. She is the recipient of numerous awards, including the Roger Jelliffe Individualized Therapy Award in 2019, the Lewis Sheiner Lecturer Award in 2022, and the Gerhard Levy Lecturer Award in 2024. She is also on the editorial boards of several prestigious clinical pharmacology journals.

Nouveau Biosciences has developed a proprietary drug discovery technology that couples the identification of synthetically lethal drugs identified through a proprietary genomic and

computational and AI driven process to the synthesis of polymer-based nanomedicines. These novel drugs have been shown to exhibit superior safety and efficacy and are helping the company move its mission of eliminating highly noxious chemotherapy from the presently employed treatment paradigms. The platform enables the creation of novel anti-cancer agents with strong intellectual property (IP), drugs that are now emerging as first-in-class and best-in-disease.

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology, the *Nouveau Nexus*™, that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company's lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies' future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact

Ashley Haston

media@nouveaubiosciences.com